Интеграция генетических факторов риска и лекарственно-ассоциированных генов при терапии биполярного расстройства: биоинформатический и системно-фармакологический анализ сигнальных путей
Drug classes and representative molecular target categories included in the analysis
the full 76-row curated drug-associated matrix is provided as Supplementary Table S2; representative genes in Table 2 span direct pharmacodynamic, mechanistic, pharmacokinetic, and pharmacogenomic layers and are not all Tier 1 targets; complete tier assignments are provided in Supplementary Table S21
Drug group | Medications included | Representative molecular targets | Main target categories | Role in this study |
Lithium | Lithium carbonate | GSK3B, GSK3A, IMPA1, IMPA2 | Intracellular pathway nodes and enzymes | Mood stabilizer block and lithium-relevant bridge to the AKAP11-GSK3B axis. |
Anticonvulsant mood stabilizers | Valproic acid, lamotrigine, carbamazepine | ABAT, ALDH5A1, HDAC2, HDAC9, SCN1A, CACNA1E, CHRNA4, ABCB1, CYP3A4 | Enzymes, ion channels, epigenetic enzymes, transporters, metabolic genes | Captures anticonvulsant and mood-stabilizing mechanisms relevant to ion-channel, GABAergic, epigenetic, and pharmacokinetic biology. |
Atypical antipsychotics | Quetiapine, olanzapine, aripiprazole, risperidone, lurasidone | DRD2, DRD3, HTR2A, HTR1A, HTR2C, HTR6, HTR7, HRH1, CHRM1, ADRA1A, ADRA1B | Dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors | Provides the main receptor-level pharmacodynamic set for pathway-relatedness analysis. |
Antidepressant pharmacogenomic block | Sertraline, escitalopram, fluoxetine, venlafaxine, bupropion | SLC6A4, SLC6A2, SLC6A3, HTR2A, CYP2D6, CYP2C19, CYP2B6 | Monoamine transporters, receptors, and pharmacogenomic enzymes | Included for pharmacogenomic and monoamine-transporter interpretation, not as universal bipolar disorder therapy. |